Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma

por Cui, Tian-ming, Liu, Yao, Wang, Jia-bei, Liu, Lian-xin
Publicado 2020

SENEBLOC, a long non-coding RNA suppresses senescence via p53-dependent and independent mechanisms

por Xu, Cheng Lin, Sang, Ben, Liu, Guang Zhi, Li, Jin Ming, Zhang, Xu Dong, Liu, Lian Xin, Thorne, Rick F, Wu, Mian
Publicado 2020

TCF4 and HuR mediated-METTL14 suppresses dissemination of colorectal cancer via N6-methyladenosine-dependent silencing of ARRDC4

por Wang, Hao, Wei, Wei, Zhang, Zhong-Yuan, Liu, Yao, Shi, Bin, Zhong, Wen, Zhang, Hou-Shun, Fang, Xin, Sun, Chun-Lei, Wang, Jia-Bei, Liu, Lian-Xin
Publicado 2021

Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma

por Capaccione, Kathleen M., Hong, Xuehui, Morgan, Katherine M., Liu, Wenyu, Bishop, Michael J., Liu, LianXin, Markert, Elke, Deen, Malik, Minerowicz, Christine, Bertino, Joseph R., Allen, Thaddeus, Pine, Sharon R.
Publicado 2014

EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma

por Yin, Da-long, Liang, Ying-jian, Zheng, Tong-sen, Song, Rui-peng, Wang, Jia-bei, Sun, Bo-shi, Pan, Shang-ha, Qu, Lian-dong, Liu, Jia-ren, Jiang, Hong-chi, Liu, Lian-xin
Publicado 2016

SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage

por Hong, Xuehui, Liu, Wenyu, Song, Ruipeng, Shah, Jamie J., Feng, Xing, Tsang, Chi Kwan, Morgan, Katherine M., Bunting, Samuel F., Inuzuka, Hiroyuki, Zheng, X. F. Steven, Shen, Zhiyuan, Sabaawy, Hatem E., Liu, LianXin, Pine, Sharon R.
Publicado 2016

Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study

por Wang, Yong-Shuai, Wang, Wei, Zhang, Sai, Zhang, Shen-Yu, Shen, Ai-Zong, Wang, Wei, Song, Hua-Chuan, Yao, Huan-Zhang, Song, Rui-Peng, Meng, Fan-Zheng, Li, Lei, Nashan, Bjoern, Wang, Ji-Zhou, Liu, Lian-Xin
Publicado 2022

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

por Shi, Guo‐Ming, Huang, Xiao‐Yong, Wen, Tian‐Fu, Song, Tian‐Qiang, Kuang, Ming, Mou, Hai‐Bo, Bao, Le‐Qun, Zhao, Hai‐Tao, Zhao, Hong, Feng, Xie‐Lin, Zhang, Bi‐Xiang, Peng, Tao, Zhang, Yu‐Bao, Li, Xiang‐Cheng, Yu, Hong‐Sheng, Cao, Yu, Liu, Lian‐Xin, Zhang, Ti, Wang, Wei‐Lin, Ran, Jiang‐Hua, Liu, Ying‐Bin, Gong, Wei, Chen, Ming‐Xia, Cao, Lian, Luo, Yang, Wang, Yan, Zhou, Hui, Yang, Guo‐Huan, Fan, Jia, Zhou, Jian
Publicado 2022